INC Research Kicks Off Sites Initiative
The goal of the Catalyst program is to strengthen collaborations with clinical research sites worldwide through network and community approaches.
INC Research officially launched the company's Catalyst program, designed to strengthen collaborations with clinical research sites worldwide. Investigative sites that take part in the program will have the opportunity to participate in an increased volume of clinical studies, according to INC. Participation is by invitation only and the initial focus is on oncology and vaccine sites in the U.S. and the Asia-Pacific region.
The program includes two components-the Catalyst Site Network and the Catalyst Community.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
